article thumbnail

With trial win, AbbVie cues up Botox for another cosmetic indication

Fierce Pharma

Already approved as an injection to reduce wrinkles in the forehead and around the eyes, AbbVie's Botox is in position to expand its cosmetic uses to the moderate to severe form of platysma prominence, a condition which causes muscle bands to protrude from the neck.

Botox 120
article thumbnail

Revance rolls out a price drop for Daxxify as it tries to challenge AbbVie's Botox

Fierce Pharma

Revance has rolled out a new strategy for Daxxify, revealing a drop in price that the company says will allow it to challenge AbbVie powerhouse Botox.

Botox 57
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Daxxify, a New Anti-Wrinkle Drug and Botox Competitor is FDA-Approved

XTalks

Daxxify was FDA-approved for similar cosmetic purposes as Botox and other neuromodulators like Dysport and Xeomin. One of the first options made available for such purposes was Botox from Allergan, brought to health practitioners’ offices in 1989. A Novel Botox Competitor.

Botox 98
article thumbnail

Botox Injections May Reduce Anxiety

Scienmag

Botox, or Botulinum toxin, a medication derived from a bacterial toxin, is commonly injected to ease wrinkles, migraines, muscle spasms, excessive sweating and incontinence.

Botox 85
article thumbnail

AI tool predicts which patients with dystonia respond to Botox treatment with 96% accuracy

Medical Xpress

Effective treatments are sparse, with botulinum toxin (Botox) injections into the affected muscles considered the first-line therapy. Dystonias are potentially disabling neurological conditions that can greatly affect quality of life.

Botox 73
article thumbnail

AbbVie says Botox rival Revance recruited its employees in bid to steal trade secrets

Fierce Pharma

AbbVie says Botox rival Revance recruited its employees in bid to steal trade secrets kdunleavy Wed, 05/03/2023 - 12:58

Botox 57
article thumbnail

AbbVie Settles Botox Rival IP Lawsuit with Evolus

BioSpace

AbbVie and its partner company, Medytox of South Korea, have settled a years-long intellectual property legal dispute with California’s Evolus over Jeuveau, a potential rival to AbbVie’s blockbuster Botox, which it gained through the acquisition of Allergan.

Botox 91